Thromboxane a2 mediates iron-overload cardiomyopathy in mice through calcineurin-nuclear factor of activated t cells signaling pathway

Circulation Journal

Volumn 77, Issue 10, 2013, Pages 2586-2595

  Lin, Heng ^a,b   Li, Hsiao Fen ^a,c   Lian, Wei Shiung ^c   Chen, Hsi Hsien ^b,d   Lan, Yi Fan ^a   Lai, Pei Fang ^a   Cheng, Ching Feng ^a,c  

^a TZU CHI UNIVERSITY   (Taiwan)

^b TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^c INSTITUTE OF BIOMEDICAL SCIENCES   (Taiwan)

^d TAIPEI MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Calcineurin nfat signaling; Cardiomyopathy; Iron overload; Thromboxane a2

Indexed keywords

15 HYDROXY 11ALPHA, 9ALPHA EPOXYMETHANOPROSTA 5, 13 DIENOIC ACID; 15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; 7 [3 [(4 PHENYLSEMICARBAZIDO) METHYL] 7 OXABICYCLO [2.2.1] HEPT 2 YL] 5 HEPTENOIC ACID; 7 [3 [(4 PHENYLSEMICARBAZIDO)METHYL] 7 OXABICYCLO[2.2.1]HEPT 2 YL] 5 HEPTENOIC ACID; CALCINEURIN; FERRITIN; INFLIXIMAB; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; IRON DEXTRAN; LUCIFERASE; MONOCYTE CHEMOTACTIC PROTEIN 1; MYELOPEROXIDASE; THROMBOXANE A2; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDIOMYOPATHY; CARDITIS; CONTROLLED STUDY; ECHOCARDIOGRAPHY; GENE TRANSFER; HEART FUNCTION; HEART MUSCLE FIBROSIS; IMMUNOBLOTTING; IRON OVERLOAD; MALE; MOUSE; NEWBORN; NONHUMAN; NUCLEAR FACTOR OF ACTIVATED T CELL; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; T LYMPHOCYTE; TRANSGENIC MOUSE; WESTERN BLOTTING;

15-HYDROXY-11 ALPHA,9 ALPHA-(EPOXYMETHANO)PROSTA-5,13-DIENOIC ACID; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; CARDIOMYOPATHIES; CELL LINE; CYTOKINES; INTERCELLULAR ADHESION MOLECULE-1; IRON OVERLOAD; MICE; MICE, KNOCKOUT; NFATC TRANSCRIPTION FACTORS; THROMBOXANE A2; VASOCONSTRICTOR AGENTS;

EID: 84884617452     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-12-1516     Document Type: Article

References (42)

1. Zurlo MG, De Stefano P, Borgna-Pignatti C, Di Palma A, Piga A, Melevendi C, et al. Survival and causes of death in thalassaemia major. Lancet 1989; 2: 27-30.
2. Olivieri NF, Brittenham GM. Iron-chelating therapy and the treatment of thalassemia. Blood 1997; 89: 739-761.
3. Gujja P, Rosing DR, Tripodi DJ, Shizukuda Y. Iron overload cardio-myopathy: Better understanding of an increasing disorder. J Am Coll Cardiol 2010; 56: 1001-1012.
4. Giardini C, Galimberti M, Lucarelli G, Polchi P, Angelucci E, Baronciani D, et al. Desferrioxamine therapy accelerates clearance of iron deposits after bone marrow transplantation for thalassaemia. Br J Haematol 1995; 89: 868-873.
5. Liu P, Olivieri N. Iron overload cardiomyopathies: New insights into an old disease. Cardiovasc Drugs Ther 1994; 8: 101-110.
6. Aldouri MA, Wonke B, Hoffbrand AV, Flynn DM, Ward SE, Agnew JE, et al. High incidence of cardiomyopathy in beta-thalassaemia patients receiving regular transfusion and iron chelation: Reversal by intensifed chelation. Acta Haematol 1990; 84: 113-117.
7. Hershko C, Link G, Cabantchik I. Pathophysiology of iron overload. Ann NY Acad Sci 1998; 850: 191-201.
8. Mattera R, Stone GP, Bahhur N, Kuryshev YA. Increased release of arachidonic acid and eicosanoids in iron-overloaded cardiomyocytes. Circulation 2001; 103: 2395-2401.
9. Kennedy I, Coleman RA, Humphrey PP, Lumley P. Studies on the characterization of prostanoid receptors. Adv Prostaglandin Thromboxane Leukot Res 1983; 11: 327-332.
10. Majerus PW. Arachidonate metabolism in vascular disorders. J Clin Invest 1983; 72: 1521-1525.
11. Johnson G, Furlan LE, Aoki N, Lefer AM. Endothelium and myo-cardial protecting actions of taprostene, a stable prostacyclin analogue, after acute myocardial ischemia and reperfusion in cats. Circ Res 1990; 66: 1362-1370.
12. Khasawneh FT, Huang JS, Mir F, Srinivasan S, Tiruppathi C, Le Breton GC. Characterization of isoprostane signaling: Evidence for a unique coordination profle of 8-iso-PGF(2alpha) with the thrombox-ane A(2) receptor, and activation of a separate cAMP-dependent inhibitory pathway in human platelets. Biochem Pharmacol 2008; 75: 2301-2315.
13. Yuhki K, Kojima F, Kashiwagi H, Kawabe J, Fujino T, Narumiya S, et al. Roles of prostanoids in the pathogenesis of cardiovascular diseases: Novel insights from knockout mouse studies. Pharmacol Ther 2011; 129: 195-205.
14. Cheng CF, Chen IL, Cheng MH, Lian WS, Lin CC, Kuo TB, et al. Acid-sensing ion channel 3, but not capsaicin receptor TRPV1, plays a protective role in isoproterenol-induced myocardial ischemia in mice. Circ J 2011; 75: 174-178.
15. Fujio Y, Nguyen T, Wencker D, Kitsis RN, Walsh K. Akt promotes survival of cardiomyocytes in vitro and protects against ischemia-reperfusion injury in mouse heart. Circulation 2000; 101: 660-667.
16. Lian WS, Lin H, Cheng WT, Kikuchi T, Cheng CF. Granulocyte-CSF induced infammation-associated cardiac thrombosis in iron loading mouse heart and can be attenuated by statin therapy. J Biomed Sci 2011; 18: 26.
17. Lin H, Lin TN, Cheung WM, Nian GM, Tseng PH, Chen SF, et al. Cyclooxygenase-1 and bicistronic cyclooxygenase-1/prostacyclin synthase gene transfer protect against ischemic cerebral infarction. Circulation 2002; 105: 1962-1969.
18. Li HF, Cheng CF, Liao WJ, Lin H, Yang RB. ATF3-mediated epigen-etic regulation protects against acute kidney injury. J Am Soc Nephrol 2010; 21: 1003-1013.
19. 2+ channels provide a major pathway for iron entry into cardiomyocytes in iron-overload cardiomyopathy. Nat Med 2003; 9: 1187-1194.
20. Muller OJ, Katus HA, Bekeredjian R. Targeting the heart with gene therapy-optimized gene delivery methods. Cardiovasc Res 2007; 73: 453-462.
21. Wacker MJ, Kosloski LM, Gilbert WJ, Touchberry CD, Moore DS, Kelly JK, et al. Inhibition of thromboxane A2-induced arrhythmias and intracellular calcium changes in cardiac myocytes by blockade of the inositol trisphosphate pathway. J Pharmacol Exp Ther 2009; 331: 917-924.
22. Cooling M, Hunter P, Crampin EJ. Modeling hypertrophic IP3 transients in the cardiac myocyte. Biophys J 2007; 93: 3421-3433.
23. Hirsh PD, Hillis LD, Campbell WB, Firth BG, Willerson JT. Release of prostaglandins and thromboxane into the coronary circulation in patients with ischemic heart disease. N Engl J Med 1981; 304: 685-691.
24. Mullane KM, Fornabaio D. Thromboxane synthetase inhibitors reduce infarct size by a platelet-dependent, aspirin-sensitive mechanism. Circ Res 1988; 62: 668-678.
25. Xiao CY, Hara A, Yuhki K, Fujino T, Ma H, Okada Y, et al. Roles of prostaglandin I(2) and thromboxane A(2) in cardiac ischemia-re-perfusion injury: A study using mice lacking their respective receptors. Circulation 2001; 104: 2210-2215.
26. Wood JC. Cardiac complications in thalassemia major. Hemoglobin 2009; 33(Suppl 1): S81-S86.
27. Guo P, Nishiyama A, Rahman M, Nagai Y, Noma T, Namba T, et al. Contribution of reactive oxygen species to the pathogenesis of left ventricular failure in Dahl salt-sensitive hypertensive rats: Effects of angiotensin II blockade. J Hypertens 2006; 24: 1097-1104.
28. Nakagomi A, Seino Y, Kohashi K, Kosugi M, Endoh Y, Kusama Y, et al. Effects of statin therapy on the production of monocyte pro-infammatory cytokines, cardiac function, and long-term prognosis in chronic heart failure patients with dyslipidemia. Circ J 2012; 76: 2130-2138.
29. Cyrus T, Ding T, Praticò D. Expression of thromboxane synthase, prostacyclin synthase and thromboxane receptor in atherosclerotic lesions: Correlation with plaque composition. Atherosclerosis 2010; 208: 376-381.
30. Kataoka M, Nagaya N, Satoh T, Itoh T, Murakami S, Iwase T, et al. A long-acting prostacyclin agonist with thromboxane inhibitory activity for pulmonary hypertension. Am J Respir Crit Care Med 2005; 172: 1575-1580.
31. Nemr R, Lasserre B, Chahine R. Effects of nicotine on thromboxane/ prostacyclin balance in myocardial ischemia. Prostaglandins Leukot Essent Fatty Acids 2003; 68: 191-195.
32. Beitz A, Taube C, Beitz J, Goos H, Graff J, Nohring J, et al. Infuence of drugs on the TXA2/PGI2 balance and on the atherogenic index in myocardial ischemia in dogs. Biomed Biochim Acta 1988; 47: S149-S152.
33. Martinuzzo ME, Maclouf J, Carreras LO, Levy-Toledano S. Antiphos-pholipid antibodies enhance thrombin-induced platelet activation and thromboxane formation. Thromb Haemost 1993; 70: 667-671.
34. Yu IS, Lin SR, Huang CC, Tseng HY, Huang PH, Shi GY, et al. TXAS-deleted mice exhibit normal thrombopoiesis, defective hemo-stasis, and resistance to arachidonate-induced death. Blood 2004; 104: 135-142.
35. Caughey GE, Pouliot M, Cleland LG, James MJ. Regulation of tumor necrosis factor-alpha and IL-1 beta synthesis by thromboxane A2 in nonadherent human monocytes. J Immunol 1997; 158: 351-358.
36. Grandel U, Fink L, Blum A, Heep M, Buerke M, Kraemer HJ, et al. Endotoxin-induced myocardial tumor necrosis factor-alpha synthesis depresses contractility of isolated rat hearts: Evidence for a role of sphingosine and cyclooxygenase-2-derived thromboxane production. Circulation 2000; 102: 2758-2764.
37. Sales KJ, Maldonado-Perez D, Grant V, Catalano RD, Wilson MR, Brown P, et al. Prostaglandin F(2alpha)-F-prostanoid receptor regulates CXCL8 expression in endometrial adenocarcinoma cells via the calcium-calcineurin-NFAT pathway. Biochim Biophys Acta 2009; 1793: 1917-1928.
38. Rosenkranz AC, Rauch BH, Freidel K, Schror K. Regulation of pro-tease-activated receptor-1 by vasodilatory prostaglandins via NFAT. Cardiovasc Res 2009; 83: 778-784.
39. Cyrus T, Yao Y, Ding T, Dogne JM, Pratico D. Thromboxane receptor blockade improves the antiatherogenic effect of thromboxane A2 suppression in LDLR KO mice. Blood 2007; 109: 3291-3296.
40. Worth NF, Berry CL, Thomas AC, Campbell JH. S18886, a selective TP receptor antagonist, inhibits development of atherosclerosis in rabbits. Atherosclerosis 2005; 183: 65-73.
41. Rengarajan J, Mittelstadt PR, Mages HW, Gerth AJ, Kroczek RA, Ashwell JD, et al. Sequential involvement of NFAT and Egr transcription factors in FasL regulation. Immunity 2000; 12: 293-300.
42. Antos CL, McKinsey TA, Frey N, Kutschke W, McAnally J, Shelton JM, et al. Activated glycogen synthase-3 beta suppresses cardiac hypertrophy in vivo. Proc Natl Acad Sci USA 2002; 99: 907-912.